Clinical trial of ShatPlus in SARS-CoV-2 Infection

INTERVENTION: Intervention1: ShatPlus along with standard treatment: 10 ml thrice a day ShatPlus along with standard treatment Control Intervention1: Standard treatment: Standard treatment as per protocol of ICMR CONDITION: Health Condition 1: B972‐ Coronavirus as the cause of diseases classified elsewhere PRIMARY OUTCOME: No. of days for negative PCR confirmatory test from nasopharyngeal swab for SARS‐Covid 2 ; Serum levels of CD4, CD8, NK cell panel CD16/CD56, CRP, IgM, IgGTimepoint: From baseline to end of study ie 10 days SECONDARY OUTCOME: Clinical status of severity ; Change in National Early Warning Score ; Hematological parameters like WBS, RBC and platelet count etc. ; Change in clinical symptom presentation ; No. of days for negative PCR confirmatory test for SARS‐Covid 2 ; Requirement of admission to intensive care unit ; Duration of hospital admission ; Total days admitted to the hospitalTimepoint: From baseline to end of study ie 10 days INCLUSION CRITERIA: SARS‐CoV‐2 positive nasopharyngeal swab Mild to Moderately severe disease (NEWS score â?¤ 8) Signed informed consent must be obtained and documented according to AYUSH GCP, and national/local regulations